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The genetic basis for the Ara-C resistance of CCRF-CEM Ara-C/8C leukemia cells was investigated.
DNA sequencing revealed that these cells expressed an equilibrative nucleoside transporter 1
(ENT1) with a single missense mutation resulting in glycine to arginine replacement (G24R). To test
the importance of this residue, additional G24 mutants were created and examined for [3H]-uridine
and [3H]-Ara-C uptake. Both a G24E and G24A mutant showed reduced ENT1-dependent activity. An
EGFP-tagged G24R ENT1 displayed plasma membrane localization even though it was unable to bind
[3H]-NBMPR, an ENT1-speciﬁc inhibitor. These results deﬁne G24 as critical amino acid for ENT1
nucleoside uptake and suggest that mutations in TM1 may provide a mechanism for Ara-C resis-
tance in CCRF-CEM Ara-C/8C cells.
 2008 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction The equilibrative nucleoside transporters (ENTs) are a Na+-inde-Cytarabine (Ara-C), a pyrimidine analog, is a conventional anti-
cancer chemotherapeutic commonly used for the treatment of
acute myeloid leukemia. Ara-C is a hydrophilic molecule that
achieves intracellular penetration via nucleoside transporter pro-
teins. Once inside the cell, this agent exerts cytotoxic effects on
proliferating cancer cells by the direct inhibition of DNA polymer-
ases and the arrest of DNA synthesis. Although Ara-C treatment of-
ten induces partial or complete remission of cancerous tissue,
many patients eventually develop resistance [1]. Thus, understand-
ing the mechanisms of resistance is important for the development
of effective anti-cancer therapies.
CCRF-CEM Ara-C/8C (Ara-C/8C) cells, a nucleoside transport-
deﬁcient T cell leukemia cell line, were isolated by single cell clon-
ing and resistance to Ara-C; these cells demonstrate cross-resis-
tance to gemcitabine and 20,30-dideoxycytidine [2,3]. Despite
these observations, the molecular defect responsible for the loss
of nucleoside transport in these cells was not elucidated.chemical Societies. Published by E
sporter 1; AraC, 1-b-D-arabi-
urine ribonucleoside (6-[(4-
, enhanced green ﬂuorescent
Pharmacology, 4009 Genetic
iversity of North Carolina @
s. Fax: +1 919 966 5640.pendent class of nucleoside transporters (SLC29) responsible for
the uptake of a large number of nucleosides and nucleoside analogs
[4]. This includes purine and pyrimidine nucleosides and analogs
such as gemcitabine, Ara-C, and ﬂudarabine [5–7]. Four distinct
members of this class of proteins have been identiﬁed (ENT1-4)
[4]. ENT1 and ENT2 are the best-characterized members of this
family; ENT1 is selectively inhibited by nitrobenzylthioinosine
(NBMPR), whereas both ENT1 and ENT2 are inhibited by dipyridi-
mole and dilazep [8]. In comparison, ENT3 is distributed mainly
within endomembranes [9] and studies suggest ENT4may function
as a monoamine/organic anion transporter [10,11].
ENTs share a common 11-transmembrane (TM) helix topology
[12] and structure–function studies suggest that amino acid resi-
dues within TM 3-6 may be involved in nucleoside binding
[13,14]. For example, site-directed mutagenesis of human ENT1
(hENT1) expressed in Saccharomyces cerevisiae demonstrated that
glycine 179 in TM5 was required for uridine transport and sensitiv-
ity to NBMPR whereas glycine 184 may partially determine target-
ing of the transporter to the plasma membrane [13]. Similarly,
glycine 154 was reported to be important for nucleoside transport
and sensitivity to the inhibitors NBMPR, dipyridamole and dilazep
[14]. However, recent studies suggest that amino acids in trans-
membrane domains other than 3-6 may also be critical for the
transport of nucleoside substrates and their analogs [15]. Speciﬁ-
cally methionine 33 in TM1 and isoleucine 429 in the TM11 of
hENT1, hENT2, and Caenorhabditis elegans ENT1 were reported tolsevier B.V. All rights reserved.
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binding of dipyridamole [15]. A report by Paproski et al. demon-
strated that tryptophan 29 within TM1 was important for inhibitor
binding and hENT1s containing mutations of W29 have altered
nucleoside transport kinetics [16].
In our study we identiﬁed a single point mutation at glycine 24
in TM1 of hENT1 in Ara-C/8C cells. To investigate the importance of
G24, we developed hENT1s with different point mutations of gly-
cine 24 and expressed these mutants in PK15 cells, a nucleoside
transport-deﬁcient cell line. The mutant hENT1s were defective
in transport activity as measured by [3H]-uridine uptake and
inhibitor binding. Thus, mutation of glycine 24 in hENT1 may ex-
plain the loss of nucleoside transport and resistance to Ara-C and
gemcitabine in Ara-C/8C cells.
2. Materials and methods
2.1. Cell culture and reagents
The nucleoside transport-deﬁcient swine epithelial cell line
PK15-NTD (PK15) was generously provided by Dr. Chung-Ming
Tse (Johns Hopkins University School of Medicine) and was main-
tained as described previously [17]. The CCRF-CEM cell line was
obtained from the ATCC (Rockville, MD.) and the CCRF-CEM Ara-
C/8C cell line, an Ara-C resistant cell line derived from the CCRF-
CEM cell line, was kindly provided by Dr. Buddy Ullman (Oregon
Health Sciences University). CCRF-CEM and Ara-C/8C cells were
maintained as described previously [2]. NBMPR (6-[(4-nitrobenzyl)
thio]-9-(b-D-ribofuranosyl) purine) was purchased from Sigma (St.
Louis, MO). [3H]-NBMPR (speciﬁc activity: 22.0 Ci/mmol), [5, 6-
3H]-Uridine (speciﬁc activity: 35–50 Ci/mmol), and [5-3H]-Ara-C
(cytosine-b-D-arabinofuranoside, speciﬁc activity: 15–30 Ci/mmol)
were obtained from Moravek Biochemicals (Brea, CA).
2.2. Total RNA extraction and cDNA synthesis
Total RNAs were extracted from CCRF-CEM and Ara-C/8C cells
with Trizol reagent (Invitrogen; Carlsbad, CA) following the manu-
facturer’s instruction. Two micrograms of total RNA was used for
ﬁrst-strand cDNA synthesis using oligo (dT) as primers and Super-
Script II RNase H– Reverse Transcriptase (SuperScriptTM First-
Strand Synthesis System for RT-PCR, Invitrogen; Carlsbad, CA).
2.3. PCR and DNA sequencing
One-tenth of the resulting ﬁrst-strand cDNA was then used for
PCR ampliﬁcation with High Fidelity pfu DNA polymerase (Invitro-
gen). The primers for amplifying the entire coding sequence of
hENT1 were 50-CCGCTCGAGATGACAACCAGTCACCTCAG-30 (sense
primer) and 50-AGACTCGAGTCACACAATTGCCCGGAACAGG-30
(antisense primer). PCR products were cloned into the TOPO blunt
cloning vector (Invitrogen) and expressed in DH5a Escherichia coli.
(Invitrogen). Plasmids were submitted for automatic sequencing
(UNC-CH Genome Analysis Facility, http://152.19.68.152/gafsite/
Main.asp).
2.4. Construction of expression vectors and transfection
hENT1 cDNA was subcloned into the pcDNA 3.1 HisC expression
vector (Invitrogen). Construction of the G24 hENT1 mutant expres-
sion vectors was performed using the Quickchange Site-directed
Mutagenesis kit (Stratagene; Cedar Creek, TX) with primers spe-
ciﬁc to hENT1; G24R sense primer (50-CTTCATGCTGGGTCTGA-
GAACGCTGCTCCCGTGG-30) and antisense primer (50-CCACGGGA-
GCAGCGTTCTCAGACCCAGCATGAAG-30), G24A sense primer (50-CTTCATGCTGGGTCTGGCAACGCTGCTCCCGTGG-30) and antisense
primer (50-CCACGGGAGCAGCGTTGCCAGACCCAGCATGAAG-30),
and G24E sense primer (50-CTTCATGCTGGGTCTGGAAACGCTG-
CTCCCGTGG-30) and antisense primer (50-CCACGGGAGCAGCGT-
TTCCAGACCCAGCATGAAG-30) each confer a missense mutation at
base pair 72. Wild-type (wt) and G24R hENT1s were subcloned
into the EGFP-C3 expression vector (Clontech; Mountain View,
CA) for confocal microscopy. Expression vectors were introduced
into PK15 or HeLa cells by Lipofectamine transfection (Invitrogen)
according to the manufacturer’s instruction.
2.5. [3H]-Uridine and [3H]-Ara-C uptake assays
The uptake of [3H]-uridine was measured in CEM cell lines or
transfected PK15 cells exactly as described previously [18]. The
same method was used to measure [3H]-Ara-C uptake with the
substitution of cold cytidine for uridine used to stop the reaction.
The protein concentration of each sample was quantitated using
Coomassie Protein Assay Reagent (Pierce; Rockford, IL).
2.6. Confocal microscopy
pEGFP-C3 constructs were transfected into HeLa cells. This cell
type was used to obtain high transfection efﬁciency and ease for
microscopy. Twenty-four hours post-transfection images were
captured using a 63 oil immersion objective on a Zeiss LSM 510
Meta confocal microscope (Thornwood, NY). Image capture was re-
solved using a 488 nm argon laser.
2.7. Isolation of membranes and [3H]-NBMPR binding assay
Crude cell membranes from the CEM cells were prepared as
described previously with minor modiﬁcation [8]. Brieﬂy, approx-
imately 5  107 cells were washed three times with room
temperature phosphate-buffered saline (PBS), suspended in
500 ll of ice-cold 5 mM Na2HPO4 buffer (pH 8.0), and sonicated
to completely lyse the cells. After a 30 min incubation on ice, the
cell membranes were washed twice (40000g centrifugation for
40 min) with ice-cold 5 mM Na2HPO4 buffer and suspended in
200 ll of the ice-cold 5 mM Na2HPO4 buffer. Binding assays were
performed at room temperature in 10 mM Tris (pH 7.1) containing
0.01% CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-pro-
panesulfonate) (w/v) to prevent non-speciﬁc binding of the radio-
ligand. Incubations were initiated by adding an aliquot of 500 lg
cell membrane to room temperature 5 mM Na2HPO4 (ﬁnal vol.
1 ml) containing 10 nM [3H]-NBMPR and were terminated after
45 min by dilution with 5 ml of ice-cold 10 mM Tris (pH 7.1) fol-
lowed by rapid ﬁltration through Whatman GF/B ﬁlters which
were then washed once with 5 ml of ice-cold 10 mM Tris (pH
7.1). Radioactivity was measured by liquid scintillation using Scin-
tisafeTM Econo-2 scintillation ﬂuid (Fisher Scientiﬁc; Pittsburgh, PA)
on a LS6500 Multi-purpose Scintillation Counter (Beckman
Coulter; Fullerton, CA). Non-speciﬁc binding of [3H]-NBMPR was
determined in the presence of 20 lM unlabelled NBMPR.3. Results
3.1. Functional loss of hENT1 activity of Ara-C/8C cells is independent
of mRNA expression
The nucleoside transport-deﬁcient Ara-C/8C cells were isolated
as a cell line highly resistant to Ara-C and gemcitabine [2,3]. Com-
parison of [3H]-uridine uptake in parental and resistant CEM cells
showed that the Ara-C/8C were completely deﬁcient in uridine up-
take (Fig. 1A). [3H]-Uridine transport was abolished with the
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demonstrating that hENT1 activity accounts for the majority of uri-
dine uptake in the CEM cell lines. In comparison, the binding of
[3H]-NBMPR to crude membrane preparations of Ara-C/8C cells
was almost completely abolished (Fig. 1B) suggesting that func-
tional hENT1 protein was absent from Ara-C/8C cells.
hENT1 mRNA expression was determined using RT-PCR. As
shown in Fig. 1C, Ara-C/8C cells expressed similar levels of hENT1
mRNA as compared to the parental CCRF-CEM cells. This observa-
tion suggests that the defect in nucleoside uptake was independent
of hENT1 expression.
3.2. Identiﬁcation of a point mutation in hENT1 from Ara-C/8C cells
that disrupts transport activity
We next determined whether hENT1 from Ara-C/8C cell line
contained mutations that would explain a loss of function. Full-
length hENT1 from Ara-C/8C cells was ampliﬁed by PCR and se-
quenced. Analysis of the hENT1 sequence from these cells revealed
a single nucleotide missense mutation resulting in the substitution
of arginine for glycine at amino acid position 24 (GGA to AGA).
Complete sequence analysis of hENT1 from Ara-C/8C cells did not
reveal any additional mutations. G24 is located in the TM1 domain
of hENT1 and is conserved amongst species and ENT2 isoforms
(Fig. 2A).
We created several point mutations of G24; substitution of ala-
nine and glutamate were performed to determine the effect of ami-
no acid size and charge on hENT1 function. Wt hENT1 and G24A,
G24E, and G24R hENT1 mutants were transfected into nucleoside
transport-deﬁcient PK15 cells and [3H]-uridine uptake was mea-
sured as an index of ENT1 activity. As shown in Fig. 2B, G24R
hENT1 was deﬁcient in [3H]-uridine transport compared to wt
hENT1. hENT1 proteins with a mutation of G24 to alanine or gluta-
mate displayed only partial transport activity when compared to
wt hENT1 (Fig. 2B). Similarly, the G24R hENT1 mutant displayedFig. 1. Comparison of [3H]-uridine uptake, [3H]-NBMPR binding, and mRNA expression b
(CEM-AraC-8C) cells were incubated with [3H]-uridine in sodium-free transport buffer fo
as described in Section 2. Data points represent sample means ± S.D. in duplicate (N = 4; *
NBMPR binding was performed as described in Section 2. Data points represent means
mRNA expression was determined as described in Section 2. Representative gel comparina deﬁciency in [3H]-Ara-C uptake; G24A hENT1 displayed partial
uptake when compared to wt hENT1 whereas G24E hENT1 was up-
take-deﬁcient (Fig. 2C). These data further indicated that glycine
24 is important for hENT1 activity and mutation of G24 severely
reduced transport activity.
3.3. The G24R hENT1 mutant maintains plasma membrane
localization but is deﬁcient in NBMPR binding
To determine if the G24R hENT1 mutant was localized to the
plasma membrane as expected, wt and G24R hENT1s were sub-
cloned into the pEGFP-C3 vector. Transfection of HeLa cells showed
that the G24R hENT1 mutant exhibited predominantly membra-
nous expression, similar to that observed with wt hENT1
(Fig. 3A). These data demonstrated that the G24 mutation did not
alter protein maturation or plasma membrane localization.
To investigate whether the G24R hENT1 mutant was sensitive
to inhibitor binding, [3H]-NBMPR binding assays were conducted
with crude cell membrane preparations from PK15 cells expressing
either wt or G24R hENT1. [3H]-NBMPR has selective afﬁnity for
ENT1 and inhibitor binding to cells expressing wt hENT1 was ob-
served (Fig. 3B). In contrast, cells expressing the G24R hENT1 mu-
tant did not display any detectable speciﬁc [3H]-NBMPR binding
suggesting that the G24R mutation affected both substrate and
inhibitor recognition.
4. Discussion
In this study we provide evidence for a novel missense muta-
tion in hENT1 that conferred resistance to nucleoside uptake in
an Ara-C resistant cell line of CCRF-CEM cells. Our results demon-
strate that a single point mutation (G24R) in TM1 results in the
generation of an inactive hENT1. G24 is an amino acid that is
highly conserved between ENT isoforms and amongst species, sug-
gestive of its importance to hENT1 function. Substitution of G24etween CCRF-CEM cells and Ara-C/8C cells. (A) 3  105 CCRF-CEM or Ara-C/8C cells
r 5 min in the presence or absence of 1.0 lM NBMPR, a selective inhibitor of hENT1,
P < 0.01 different from –NBMPR, #P < 0.01 different from parental cell line). (B) [3H]-
± S.D. from samples run in triplicate (N = 2; *P < 0.01). C) RT-PCR analysis of hENT1
g mRNA levels in the parental CCRF-CEM cell line and CCRF-CEM-AraC-8C cell line.
Fig. 2. Substitution of G24 in hENT1 disrupts nucleoside and Ara-C transport activity. (A) Cross-species comparison of amino acids 13–33 of ENT1 and ENT2. Arrow denotes
G24. (B) Wt hENT1 and G24A, G24E, and G24R hENT1 mutants were expressed separately in PK15 cells (6  104) and [3H]-uridine uptake was performed for 20, 40, and
60 min as described in Section 2. Average transport by wt hENT1 was approx. 4.19 pmol/min/mg protein. Data points represent means ± S.D. of samples run in quadruplicate
(N = 1; *P < 0.01 different from control). (C) Wt hENT1 and G24A, G24E, and G24R hENT1 mutants were expressed separately in PK15 cells (6  104) and [3H]-Ara-C uptake
was performed for 2 h in the presence or absence of 1 lM NBMPR as described in Section 2. Average transport by wt hENT1 was approx. 2.08 pmol/min/mg protein. Data
points represent mean ± S.D. of samples run in quadruplicate (N = 1; *P < 0.01 different from control, #P < 0.01 different from –NBMPR).
Fig. 3. G24R hENT1 mutant lacks [3H]-NBMPR binding even though plasma membrane expression is maintained. (A) Wt and G24R hENT1 expression was observed using
confocal microscopy. Image ﬁelds are representative of expression. Arrows denote approximate plasma membrane location. (B) Wt hENT1 and G24R hENT1 were transfected
separately into PK15 cells. Forty-eight hours post-transfection cells were lysed, the membranes were isolated and [3H]-NBMPR binding to the isolated membrane was
determined as described in Materials and Methods. Data points represent the mean ± S.D. (N = 3; *P < 0.01 different from control).
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tance of G24 in ENT1 recognition of substrates. Moreover, G24 may
be an important contact for inhibitor recognition since G24R mu-
tants of hENT1 did not bind [3H]-NBMPR. Partial [3H]-Ara-C trans-
port was observed with the G24A mutation, which may be due to
the similarity of the amino acids. Importantly, our data suggest
that differences in hENT1 G24 mutant activity were not due to dif-
ferential expression but due to a functional difference since the wt
and G24R hENT1 proteins had dissimilar [3H]-uridine transport/
[3H]-NBMPR binding ratios (2.54 ± 0.10 vs. 0.67 ± 0.02). Thus these
studies are the ﬁrst to identify this conserved amino acid as an
important determinant for nucleoside recognition and uptake.
The G24R point mutation in hENT1 may affect several processes
related to the functional activity of hENT1 including substrate
binding, protein folding or targeting of hENT1 to the plasma
membrane. Topology predictions (SOSUI program; http://bp.nuap.
nagoya-u.ac.jp/sosui/) suggest that G24R hENT1 is capable of tar-
geting to plasmamembrane similarly to the wt hENT1. This predic-
tion is supported by our data showing similar membranous
localization of EGFP-tagged wt and G24R hENT1. Our studies also
show that G24R hENT1 is incapable of binding the inhibitor
NBMPR. This may result from a disruption of the substrate-binding
site since NBMPR, a purine analog, is expected to bind at or near
the substrate-binding pocket [13,14]. Recent studies have shown
that amino acids in close proximity (M33 and W29) are important
to hENT1 nucleoside transport and inhibitor binding [15,16]. Based
on these observations, we speculate that the G24R substitution at
this position similarly interferes with binding of nucleosides and
nucleoside analogs to hENT1. Thus, TM1 may be a topologically-
sensitive portion of hENT1 making the proper orientation of TM1
necessary for protein function.
ENT-mediated transport of nucleoside analogs is often the rate-
limiting step for drug-induced cell cytotoxicity [6]. Thus, it is not
surprising that studies have found a positive correlation between
the expression of hENT1 and cancer cell sensitivity to the nucleo-
side analogs Ara-C [19] and gemcitabine [20]. The reduction in
hENT1 expression is a common mechanism for resistance to anti-
metabolite treatment of cancer [7,21]. In addition, a recent study
using an Ara-C-resistant CCRF-CEM cell line reported that genetic
mutations of hENT1 that alter mRNA splicing and protein transla-
tion provide mechanisms for resistance to drug treatment [22].
In conclusion, these studies provide new information on the spe-
ciﬁc role of G24 in the TM1 domain of ENT1 in nucleoside recogni-
tion and uptake. Expression of a G24R hENT1 mutant provides the
ﬁrst molecular explanation for the loss of hENT1-dependent nucle-
oside uptake in the Ara-C/8C cells and indicates that mutation of
this amino acid could result in resistance to Ara-C treatment.
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